Six tools now dominate the market for tracking how brands show up in ChatGPT, Perplexity, Gemini, and Google’s AI Overviews: Profound, Peec AI, Scrunch AI, Otterly AI, Ahrefs Brand Radar, and Semrush AI Visibility Toolkit. All six report mentions, citations, sentiment, and share of voice. None of them classify a claim as on-label or off-label, flag the absence of a boxed warning, recognize a REMS-restricted drug, or route a safety complaint buried in an AI answer to a pharmacovigilance team on a regulatory clock. They were built to solve a SaaS and e-commerce problem: does the model recommend our product over a competitor’s. Pharmaceutical marketing has a different problem: does the model describe our product in a way that would pass a Medical, Legal, and Regulatory review. Those are not the same question, and none of the six tools compared here were designed to answer the second one.
What “AI Visibility” Actually Measures
The category built around tools like Profound and Peec AI goes by several names: generative engine optimization (GEO), answer engine optimization (AEO), or simply AI visibility tracking. Regardless of the label, the mechanics are close to identical across vendors. A platform runs a set of prompts against AI engines on a recurring schedule, records whether a brand was named in the response, records which sources the model cited, and scores the pattern over time against competitors.[1]
Mentions, Citations, and Share of Voice
A mention means the AI named the brand. A citation means the AI linked to the brand’s own content as a source, even without naming the brand explicitly. Ahrefs Brand Radar tracks both separately and treats the difference as a signal of whether a model trusts a brand’s own site or is relying on third-party coverage instead.[2] Peec AI reduces its own tracking to three core metrics: visibility, or how often a brand is mentioned; position, or where in the answer it appears; and sentiment, the tone in which it is described.[3] Semrush AI Visibility Toolkit compresses this further into a single AI Visibility Score of Low, Medium, or High, calculated from the volume of AI-generated responses it samples across the covered engines.[4]
Built for a Different Category of Buyer
Vendor documentation is explicit about who these tools are built for. Profound’s own ideal customer profile describes companies with 50 to 1,000-plus employees at Series B or later, generating $10 million or more in annual recurring revenue, in SaaS, fintech, e-commerce, or retail, with reference customers including Ramp, Target, Walmart, and Statsig.[5] Peec AI lists Axel Springer, Chanel, n8n, ElevenLabs, and TUI among its customers.[6] None of the six platforms compared in this article names a pharmaceutical manufacturer, a med-comms agency, or a pharmacovigilance vendor among its published reference customers, and none of their public feature documentation mentions FDA promotional regulations, prescribing information, or drug safety labeling.
The Six Platforms, and What Each One Actually Tracks
Profound: Enterprise AEO Built for Marketing and PR Teams
Profound is the best-funded entrant in the category. As of September 2026 the company says more than 2,500 brands and roughly one-third of the Fortune 100 use the platform, following a $180 million Series D round that valued the company at $1.8 billion.[7] Its core surfaces are Answer Engine Insights, which shows how often a brand appears across ChatGPT, Perplexity, Gemini, and Google AI Overviews with citation and sentiment detail; Prompt Volumes, a separate research tool for what people are asking AI systems in a given category; and Agent Analytics, which tracks how AI crawlers interact with a brand’s own website.[8] A newer Agents feature automates content research, drafting, and CMS publishing based on the visibility data the platform collects.[9] None of these surfaces classify a generated claim against a regulatory standard; they classify it against brand share of voice.
Peec AI: Prompt-Level Visibility and Brand Perception
Peec AI, a Paris-founded platform that has raised $21 million in funding, runs a tighter loop than Profound: fire a curated set of prompts at the AI engines on a daily schedule, record how the brand and named competitors show up, and surface where visibility is being lost.[10] Its base plans cover ChatGPT, Perplexity, and Google AI Overviews, with Claude, Gemini, and other engines available as paid add-ons.[11] A newer Brand Perception feature shows how AI systems characterize a brand qualitatively, and which sources are driving that characterization, but the underlying classification categories are marketing categories: positive, neutral, negative, and the arguments a model makes for and against the brand.[12] There is no category for “unapproved indication” or “missing risk information.”
Scrunch AI: Acquired by Sitecore, Built to Deliver Content to Agents
Scrunch AI distinguishes itself by trying to shape what AI crawlers actually ingest, not just measure the result. Its Agent Experience Platform serves a compressed, machine-readable version of a brand’s site directly to AI agents.[13] The platform’s trajectory is also the clearest evidence of how fast this market is consolidating: enterprise software vendor Sitecore acquired Scrunch for a reported $225 million in June 2026, folding AI answer-engine visibility into an enterprise content management platform.[14] Scrunch’s Core plan, at $250 per month, covers four engines; the custom Enterprise tier adds Claude, Gemini, Meta AI, Google AI Mode, and Grok for nine total.[15] Its site audits flag whether AI crawlers can render a page’s content correctly, which is a genuinely useful technical capability for a pharma content team, but the audit checks for renderability, not for whether the page carries the fair-balance risk information a promotional claim legally requires.
Otterly AI: The Low-Cost, High-Volume Entry Point
Otterly AI, founded in Vienna in October 2024 and self-funded since launch, has grown to more than 40,000 users by August 2026 on the strength of a $29-per-month entry tier.[16] Its core product tracks daily prompts across four engines, a Brand Visibility Index that combines multiple signals into a single KPI, and a GEO audit with a SWOT-style breakdown of a site’s AI-readiness.[17] Reviewers consistently flag the GEO audit as the platform’s strongest feature at its price point.[18] Otterly’s pricing structure, which scales primarily on prompt volume and engine add-ons rather than on regulated-content workflow, reflects a product built for lean marketing and SEO teams rather than for MLR-reviewed content.
Ahrefs Brand Radar: A Search-Data-Driven Approach
Ahrefs built Brand Radar on top of its existing search-index infrastructure, which by early 2026 processed more than 239 million prompts a month across AI Overviews, AI Mode, ChatGPT, Copilot, Gemini, and Perplexity, drawing on a base of more than 150 million real, observed search queries rather than synthetic prompts written by the tool itself.[19] That grounding in real query volume is a genuine advantage for understanding what people are actually asking about a drug or condition. Brand Radar’s primary metrics are mentions, citations, estimated impressions, and AI Share of Voice, and it has extended beta tracking into YouTube transcripts, Reddit threads, and TikTok content as upstream signals that shape what AI systems later say.[20] Claude is available only through custom API-based prompt tracking rather than as part of the standard organic index, a coverage gap several reviewers flag as significant given Claude’s use among clinicians and researchers.[21]
Semrush AI Visibility Toolkit: Now an Adobe Product
Semrush sells its AI Visibility Toolkit as a $99-per-month, per-domain add-on covering ChatGPT, Gemini, Perplexity, and Google AI Mode and AI Overviews, with Claude, Copilot, and DeepSeek reserved for a separate, more expensive Enterprise AIO product.[22] The toolkit ships as six reports, including a Visibility Overview, Brand Performance, and AI Audience Insights, built around a proprietary AI Visibility Score.[23] Like Scrunch, Semrush’s ownership changed hands in 2026: Adobe completed its roughly $1.9 billion acquisition of Semrush on April 28, 2026, and the AI visibility product now sits inside Adobe’s Customer Experience Orchestration business.[24] As with the other five tools, Semrush’s reports measure exposure and sentiment. They do not check a generated answer against a drug’s approved indications or its boxed-warning language.
Mentions, citations, GEO audit, Brand Visibility Index
Google AI Overviews, ChatGPT, Perplexity, Copilot
$29/mo (Lite)
Self-funded, 40,000+ users[16]
Ahrefs Brand Radar
Mentions, citations, impressions, Share of Voice
ChatGPT, Perplexity, Copilot, AI Overviews, AI Mode
Bundled in Ahrefs plans
239M+ prompts/month indexed[19]
Semrush AI Visibility Toolkit
AI Visibility Score, brand performance, prompt research
ChatGPT, Gemini, Perplexity, AI Mode, AI Overviews
$99/mo per domain
Acquired by Adobe, ~$1.9B[24]
What None of the Six Actually Classify: On-Label vs. Off-Label
How the On-Label / Off-Label Line Works Under the FDCA
The Federal Food, Drug, and Cosmetic Act does not contain the phrase “off-label promotion.” The prohibition is constructed indirectly: a drug is misbranded if its labeling lacks “adequate directions for use,” and FDA’s regulations tie adequate directions to the drug’s approved “intended use.” When a manufacturer’s own promotional claims describe a use, population, dose, or duration the label does not cover, FDA can treat those claims as evidence that the drug is being distributed for an unapproved intended use, which triggers the misbranding provisions.[25] Physicians remain free to prescribe off-label; the restriction runs against the manufacturer’s promotion, not the physician’s practice of medicine.[26] This is not a stylistic nuance. It is the legal hinge that the entire promotional-review function inside a pharma company exists to manage, and it requires knowing, for a specific drug, exactly what the current approved label says.
Why “Positive Sentiment” Is the Wrong Question
A generic AI visibility platform scores a mention as positive, neutral, or negative. That scale answers a marketing question and is silent on the only question that matters for promotional compliance: does the described use match the approved label. An AI answer that enthusiastically recommends a second-line oncology drug as first-line therapy would score as a strongly positive mention on every one of the six platforms compared here, and would simultaneously describe exactly the kind of unapproved-use claim that draws an OPDP warning letter when a company makes it directly.[27] None of the six platforms’ public documentation describes a workflow for checking a generated claim against a specific drug’s current indications section.
An Original Taxonomy: Four Ways a Favorable AI Mention Becomes a Compliance Problem
Pulling from how off-label promotion liability is actually constructed under the FDCA, a favorable AI-generated mention of a branded drug can fail compliance review in at least four distinct ways that a sentiment-only score cannot distinguish between:
Indication drift. The AI recommends the drug for a disease, line of therapy, or patient population outside its approved indications, the pattern the industry piece “Health AI Assistants” flags when describing how models fail to distinguish a drug’s approved treatment line from other uses it may have been studied for.[28]
Dosing or duration drift. The AI states a dose, frequency, or treatment duration that differs from the approved label, without necessarily naming a different indication at all.
Population drift. The AI extends a recommendation to a patient population, such as pediatric patients or pregnant patients, that the label excludes or restricts.
Comparative drift. The AI generates a head-to-head comparison implying superiority or equivalence that no approved labeling or company-sponsored study supports, a distinct promotional risk under fair-balance and substantiation rules even when the underlying indication claim is accurate.
A platform built to track “was the brand mentioned favorably” cannot, by construction, separate these four failure modes from an accurate, fully on-label mention, because all four register as the same thing on a sentiment axis: positive.
Boxed Warnings Do Not Show Up in a Sentiment Score
What Fair Balance Actually Requires
Under 21 CFR 202.1, prescription drug advertising must present a fair balance between effectiveness claims and risk information, and an advertisement is misleading if it suggests a drug has less serious side effects or contraindications than its labeling indicates.[29] FDA’s own guidance is specific that risk information must be presented with prominence and depth comparable to the effectiveness claims sitting next to it, not merely appended somewhere in the same document.[30] A drug’s boxed warning, the most serious category of safety information FDA can require in labeling, is the clearest test case: a promotional claim that describes a drug’s benefits without any proportionate acknowledgment of a boxed risk is a textbook fair-balance violation when a company makes it.
A Worked Example
Isotretinoin carries one of the most extensively documented boxed warnings in the current label, for severe fetal harm if taken during pregnancy, among other serious risks, and its prescribing is governed by a dedicated risk program rather than by standard labeling alone. If an AI system responds to a query about isotretinoin with an enthusiastic, benefit-forward answer and no mention of the pregnancy risk or the program that governs its dispensing, every one of the six visibility platforms in this article would log that as a positive brand mention. None would flag that the response omitted the single most consequential piece of safety information tied to the drug. A brand team relying on a generic dashboard’s sentiment score would see a metric moving in the right direction while missing the exact pattern that would draw the most severe FDA scrutiny if the company itself had generated the claim.
REMS-Restricted Drugs Need a Fundamentally Different Kind of Monitoring
What a REMS Actually Constrains
A Risk Evaluation and Mitigation Strategy, authorized under Section 505-1 of the FD&C Act as added by the 2007 FDA Amendments Act, is a required safety program FDA can impose when a drug’s serious risks demand controls beyond standard professional labeling.[31] A REMS can combine a Medication Guide, a structured provider communication plan, and Elements to Assure Safe Use, which may include prescriber certification, restricted dispensing sites, mandatory patient monitoring, or registry enrollment.[32] Isotretinoin’s iPLEDGE program and clozapine’s REMS, which requires documented neutrophil-count monitoring before each dispense, are examples of ETASU-based programs built around exactly this kind of structural restriction, not just a risk statement in the label.
Why “Visibility” Is the Wrong Goal for a REMS Drug
For most branded drugs, more favorable AI visibility is directionally good for the brand team, all else equal. For a REMS drug, that assumption breaks. An AI-generated answer that makes a REMS drug sound broadly accessible, without surfacing the certification, monitoring, or registry requirements that actually govern who can prescribe and dispense it, can function as a form of off-label-adjacent risk minimization even when it never states an unapproved indication. None of the six platforms compared here maintain a list of which tracked brands carry a REMS, let alone which specific ETASU element an AI answer is silently omitting. That is a pharma-specific data layer, not a generic AI-monitoring feature, and none of the six general platforms build it.
Pharmacovigilance Runs on a Clock the Generic Dashboards Don’t Know Exists
The Duty to Report “Of Which the Company Becomes Aware”
Postmarketing safety reporting obligations do not wait for a company to go looking. Current guidance reflected in FDA’s framework treats unsolicited reports of suspected adverse reactions surfaced through the internet or digital media as spontaneous reports, subject to the same expedited reporting clock as any other spontaneous report, and that clock starts the moment any employee of the company becomes aware of the minimum information needed for a valid case report.[33] Companies are not required to proactively monitor every third-party site for adverse events, but under the ICH framework FDA’s guidance reflects, once a company becomes aware of an adverse event mentioned on a third-party platform, it must address it.[34]
Why a Weekly AI-Visibility Report Misses the Point
Every one of the six platforms in this comparison is built around scheduled, batched reporting: daily prompt runs rolled into weekly or monthly dashboards, delivered to a marketing or SEO stakeholder. That cadence is well suited to tracking share-of-voice trends. It is poorly suited to a regulatory obligation that is triggered the moment a company becomes aware of a safety signal, not the moment a weekly report happens to surface one. An AI chatbot answer describing a patient’s adverse experience with a drug, surfaced inside a marketing dashboard three or seven days after the fact, does not reset the awareness clock to the report date; the clock ran from the moment the information entered the company’s awareness, however that happened. A monitoring tool that was never designed to route a flagged response to a pharmacovigilance intake queue within hours, rather than to a marketing Slack channel within a week, is not built for that obligation.
What a PV-Team-Ready Output Would Actually Require
A workflow built for pharmacovigilance intake, rather than for marketing reporting, would need to do at least three things none of the six generic platforms describe doing: identify language in a generated AI response that resembles a reportable adverse event rather than general sentiment; route that flagged content to a PV intake system on a same-day basis rather than a weekly digest; and preserve the original AI response, prompt, model, and timestamp as a retrievable record, since a case report built from a digital source still needs the same minimum information, an identifiable reporter, patient, suspect product, and adverse event, that any spontaneous report requires.[35] This is closer to a compliance intake pipeline than to a brand-visibility dashboard, and it is the kind of workflow that a small set of pharma-specific vendors, rather than the six horizontal GEO platforms, have started to build.
The Regulatory Backdrop: FDA Is Already Running AI Against This Exact Content
The September 2025 DTC Crackdown, by the Numbers
On September 9, 2025, HHS and FDA jointly announced a crackdown on what the agency called deceptive drug advertising, sending what FDA described as thousands of warning letters and roughly 100 cease-and-desist letters.[36] By the end of 2025, FDA had issued 74 enforcement letters specifically to pharmaceutical and biologic manufacturers, 42 of them targeting DTC television advertisements, making 2025 the highest annual total for this kind of enforcement in nearly 25 years.[37] The named recipients of the September 9 letters included AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Novartis, and Takeda, along with three separate letters to Eli Lilly and letters to Novo Nordisk, Aytu BioPharma, Alora Pharmaceuticals, and CSL Behring.[38] The volume alone signals a materially more aggressive posture than the roughly single-digit-to-low-teens annual letter counts OPDP had issued in recent prior years.
FDA’s Own AI Is Reading This Content Too
Medical disclaimers on health-related AI outputs fell from 26.3 percent to under 1 percent between 2022 and 2025, even as those same AI systems increasingly present aggregated patient claims as though they carried clinical weight.[39]
That statistic describes the consumer-facing side of the problem. On the enforcement side, FDA has been explicit that artificial intelligence is now part of how it finds violations in the first place. In an interview describing the agency’s approach, regulatory attorney Edgar Asebey noted that AI lets FDA “quickly flag potential violations of the Food, Drug, and Cosmetic Act” and detect misleading or unbalanced risk-benefit presentations at a scale manual review could not match.[40] FDA’s internal AI system, Elsa, built on Anthropic’s Claude model and run in a secured GovCloud environment, is already used for summarizing adverse events, comparing drug labels, and helping identify high-priority inspection targets.[41] Legal analysis of Elsa’s expanding role notes that as FDA further integrates AI into its surveillance functions, it becomes easier for the agency to analyze public statements, advertising practices, and safety disclosures alongside adverse event data to identify violative patterns that might previously have gone unnoticed.[42] The practical result is a widening gap in capability: the regulator’s AI is explicitly trained to look for fair-balance failures and unbalanced risk-benefit claims, while the AI-visibility tools many marketing teams are buying were never built to look for those things at all.
The January 2026 FDA-EMA Guiding Principles
On January 14, 2026, FDA and EMA jointly published ten guiding principles for good AI practice in drug development, covering AI systems used to generate or analyze evidence across the nonclinical, clinical, postmarketing, and manufacturing phases of a drug’s lifecycle.[43] The principles are not binding requirements, and neither agency has yet issued specific guidance stating that AI-generated public answers about a drug constitute a channel subject to the same promotional or pharmacovigilance obligations as a company’s own website or social media account. But the direction of travel is unambiguous: both agencies are building the regulatory infrastructure to treat AI-mediated information about a drug as part of the same lifecycle oversight that already covers labeling, advertising, and safety surveillance, and industry analysis already describes the extension of digital-channel monitoring duties to AI outputs as “hard to dismiss” even before a regulator formally rules on it.[44]
What Pharma-Specific Monitoring Does Differently
The compliance gap described above has not gone unnoticed inside the industry that would have to close it. A recent market analysis of AI-output compliance monitoring points to a small set of vertical specialists, including Sorcero, Norm.ai, and WhizAI, building what it calls semantic compliance agents capable of interpreting biomedical context, detecting off-label intent, and automating pharmacovigilance intake, distinct from the horizontal AI-visibility category this article compares.[45] The same analysis frames the underlying driver bluntly: with OPDP signaling a return to aggressive enforcement and leveraging its own AI tools to surveil the digital landscape, pharmaceutical companies are increasingly compelled to deploy “AI to watch AI.”[46]
Even buying guides written specifically for pharmaceutical marketing teams illustrate the gap rather than closing it. One industry resource built to recommend AI visibility tools for pharmaceutical companies names Trakkr, Profound, Semrush AI Visibility Toolkit, Ahrefs Brand Radar, and LLMrefs as its picks, while separately noting that pharma teams should independently verify “whether AI cites FDA, label, OPDP, clinical-trial, payer, patient-support, or media sources,” an acknowledgment that the recommended tools themselves do not perform that verification.[47] A comparison guide to GEO and AEO tools for pharma and healthcare brands lists SOC 2 Type II, HIPAA compliance, SSO, and audit logs as its compliance criteria, security and access controls, rather than any capability tied to promotional-content classification, boxed-warning detection, or REMS awareness.[48] That distinction matters: a platform can be fully SOC 2 compliant and encrypt its data at rest while still having no concept of what a boxed warning is.
DrugChatter, a monitoring platform built specifically for pharmaceutical and pharmacovigilance audiences, illustrates what a pharma-specific approach to this problem looks like in practice: applying label-aware classification to AI-generated answers about a specific drug, rather than scoring every mention on the same generic positive-neutral-negative scale a SaaS or retail brand would use. It is one example of the category, not a replacement for the primary evidence, regulatory guidance, and labeling that any compliance decision ultimately has to rest on.
A Decision Framework: When a Generic Tool Is Good Enough, and When It Isn’t
Content is typically not drug-specific; still worth spot-checking for inadvertent off-label framing.
Branded, on-label promotional content visibility
No, not alone
Requires classification against the current approved label, which no generic tool performs.
Boxed-warning or REMS-restricted drugs
No
Requires drug-specific risk-data awareness generic sentiment scoring does not include.
Pharmacovigilance-relevant signal detection in AI answers
No
Requires same-day-aware routing to PV intake, not weekly marketing dashboards.
What This Means for Each Function
For Marketing
A generic GEO tool remains genuinely useful for what it was built to do: understanding whether a brand shows up at all, which competitors are winning the same prompts, and whether the sites AI models cite include the company’s own domain. Treat that output as directional awareness, not as a compliance signal, and do not let a rising visibility score substitute for MLR review of what the AI is actually saying.
For Regulatory Affairs
The September 2025 enforcement wave and FDA’s own AI-assisted surveillance both point toward a regulator that is getting faster at finding fair-balance and off-label problems in company-controlled channels. AI-generated third-party answers are not yet formally a monitored channel, but treating them as effectively unmonitored, simply because no current vendor classifies them against label language, is a widening exposure rather than a shrinking one.
For Pharmacovigilance
The 15-day-class awareness clock that governs spontaneous adverse event reports does not pause for a weekly marketing report cadence. Any AI-monitoring tool feeding into a PV workflow needs a same-day, not same-week, routing path for content that resembles a reportable event.
For Medical Affairs
Medical affairs teams already field questions about whether AI systems are accurately representing clinical evidence for a compound. The indication-drift and dosing-drift patterns described above are the practical, day-to-day version of that concern, and they are invisible to a sentiment-only dashboard.
Key Takeaways
Six platforms, Profound, Peec AI, Scrunch AI, Otterly AI, Ahrefs Brand Radar, and Semrush AI Visibility Toolkit, dominate general AI-visibility tracking, and none names a pharmaceutical manufacturer among its published reference customers.
All six score AI mentions on marketing metrics: visibility, citations, position, and sentiment. None classifies a generated claim as on-label or off-label against a drug’s current approved indications.
FDA’s fair-balance rule under 21 CFR 202.1 requires risk information comparable in depth to effectiveness claims; a favorable AI mention with no boxed-warning context would pass every generic tool’s sentiment check while failing that standard if a company had generated it directly.
REMS-restricted drugs, governed by Elements to Assure Safe Use under Section 505-1 of the FD&C Act, need risk-program awareness that no generic visibility platform tracks.
Pharmacovigilance reporting duties trigger the moment a company becomes aware of a reportable adverse event, a same-day standard that weekly or monthly AI-visibility dashboards are not built to meet.
FDA issued 74 enforcement letters to pharmaceutical and biologic manufacturers in 2025, the highest annual total in nearly 25 years, and is using its own AI system, Elsa, built on Anthropic’s Claude model, to help surveil promotional content at scale.
A small set of vertical compliance-AI vendors, including Sorcero, Norm.ai, and WhizAI, along with pharma-specific monitoring platforms like DrugChatter, are building the classification and PV-routing layer the six horizontal GEO tools do not.
FAQ
Is a general AI visibility tool like Profound or Semrush technically prohibited for pharma use?
No. Nothing in FDA regulation prohibits a pharma company from using a general GEO platform to track brand mentions. The risk is not the tool’s legality; it is treating its output as a compliance signal when the tool was never built to check content against label language, boxed warnings, or REMS requirements.
Do any of the six platforms compared here mention FDA compliance in their own marketing?
Based on the public feature documentation reviewed for this article, none of the six describe FDA promotional regulations, prescribing information, or pharmacovigilance workflows as a supported use case.
What is the difference between an AI mention and an AI citation?
A mention means the AI named the brand in its answer. A citation means the AI linked to the brand’s own content as a source, even if the brand was not named directly in the text.[2]
Does a company have to monitor what AI chatbots say about its drugs?
Neither FDA nor EMA has formally designated AI-generated third-party answers as a monitored channel subject to the same proactive-monitoring duty as a company’s own website. However, once a company becomes aware of an adverse event mentioned anywhere, including in an AI-generated response, current spontaneous-reporting timeframes apply from the moment of that awareness.[33]
What triggers an FDA off-label promotion violation?
Off-label promotion liability is built on the FDCA’s misbranding provisions: a drug is misbranded if it lacks adequate directions for its actual intended use, and a manufacturer’s own promotional claims can serve as evidence of an intended use the label does not cover.[25] Physician prescribing off-label is not restricted; manufacturer promotion of unapproved uses is.
What is a REMS, in plain terms?
A Risk Evaluation and Mitigation Strategy is an FDA-required safety program for drugs whose serious risks need controls beyond standard labeling, which can include prescriber certification, restricted dispensing, mandatory monitoring, or registry enrollment.[31]
Why did Scrunch AI and Semrush’s AI Visibility Toolkit both change ownership in 2026?
Both moves reflect the same trend: established enterprise software vendors buying into the AI-visibility category rather than building it internally. Sitecore acquired Scrunch for a reported $225 million in June 2026, and Adobe completed its roughly $1.9 billion acquisition of Semrush in April 2026, folding the AI Visibility Toolkit into Adobe’s Customer Experience Orchestration business.[14][24]
Is FDA actually using AI to find drug advertising violations?
Yes. FDA’s internal AI system, Elsa, is used for tasks including summarizing adverse events and helping identify inspection targets, and the agency has said AI helps it flag potential FDCA violations, including unbalanced risk-benefit presentations, at greater scale than manual review allows.[40][41]
Which AI engines do the six platforms actually cover on their entry-level plans?
Coverage varies and changes frequently. As of 2026, most entry tiers cover ChatGPT, Perplexity, and Google AI Overviews as a baseline, with Claude, Gemini, and other engines frequently gated behind higher-priced or Enterprise plans across Peec AI, Scrunch AI, and Semrush specifically.[11][15][22]
Do pharma-specific AI monitoring tools replace the need for MLR review?
No. Every pharma-specific monitoring approach, including DrugChatter’s, is a detection and awareness layer, not a substitute for a company’s own Medical, Legal, and Regulatory review process or for the primary evidence, current labeling, and regulatory guidance that any promotional or safety decision has to rest on.
References
Peec AI. (2026, August). What is Peec AI? Features, pricing, and alternatives (2026). GeoToolbox. https://geotoolbox.ai/blog/what-is-peec-ai
Ahrefs. (2026). Free AI visibility checker by Ahrefs: Track your brand in AI search. https://ahrefs.com/ai-visibility-checker
Surferstack. (2026, February 21). The complete Peec AI review: Features, pricing, limitations and better alternatives in 2026. https://surferstack.com/guides/the-complete-peec-ai-review-features-pricing-limitations-and-better-alternatives-in-2026
BehindRankings. (2026, August 11). Semrush AI Visibility Toolkit review (2026): Worth $99/mo? https://behindrankings.com/semrush-ai-seo-toolkit-review/
CheckThat.ai. (2026). Profound: Details, reviews, pricing, and features. https://checkthat.ai/brands/tryprofound
Surferstack. (2026, February 21). The complete Peec AI review. https://surferstack.com/guides/the-complete-peec-ai-review-features-pricing-limitations-and-better-alternatives-in-2026
Scalenut. (2026, September). Profound AI review 2026: Strong data, but here’s the real story. https://www.scalenut.com/blogs/profound-ai-reviews
Indexly. (2026, July 13). Profound AI review 2026: Features, pricing, pros, cons. https://indexly.ai/blog/profound-ai-review/
Indexly. (2026, July 13). Profound AI review 2026. https://indexly.ai/blog/profound-ai-review/
GeoToolbox. (2026, August). What is Peec AI? Features, pricing, and alternatives (2026). https://geotoolbox.ai/blog/what-is-peec-ai
Discovered Labs. (2026, May 18). Peec AI review 2026: Best for AI visibility monitoring? https://discoveredlabs.com/blog/peec-ai-review-best-for-ai-visibility-monitoring-use-cases-limits-alternatives
EverythingPR. (2026). Scrunch AI: The Agent Experience Platform, explained. https://everything-pr.com/scrunch-ai-agent-experience-platform-decibel-mayfield-homebrew-geo-profile
MediaCopilot. (2026, June 3). Sitecore acquires GEO startup Scrunch for around $225 million. https://mediacopilot.ai/sitecore-acquires-scrunch-geo-startup-225m/
GeoToolbox. (2026, August). Scrunch AI review (2026). https://geotoolbox.ai/blog/scrunch-ai-review
SE Ranking Visible. (2026, August). Otterly AI review 2026: Features, pricing, and who it’s for. https://visible.seranking.com/blog/otterly-ai-review/
Geoptie. (2026, July 24). Otterly AI review 2026: Is the $29 plan enough? https://geoptie.com/blog/otterly-ai-review
Geoptie. (2026, July 24). Otterly AI review 2026. https://geoptie.com/blog/otterly-ai-review
Ahrefs. (2026). Product announcement: Ahrefs adds YouTube and Reddit tracking to Brand Radar. https://ahrefs.com/blog/product-announcement-ahrefs-adds-youtube-and-reddit-tracking-to-brand-radar/
Dageno AI. (2026, August 3). Ahrefs Brand Radar review 2026: Features, pricing, and who it’s really for. https://dageno.ai/blog/ahrefs-brand-radar-review
EWR Digital. (2026, July 11). Ahrefs Brand Radar alternatives and review: Is it worth it? (2026). https://www.ewrdigital.com/blog/ahrefs-brand-radar-review-alternatives-pricing-comparison
Meev. (2026, July 19). Semrush AI Visibility Toolkit: What it does, pricing and alternatives. https://meev.ai/reviews/semrush-ai-visibility-toolkit
BehindRankings. (2026, August 11). Semrush AI Visibility Toolkit review (2026). https://behindrankings.com/semrush-ai-seo-toolkit-review/
Meev. (2026, July 19). Semrush AI Visibility Toolkit: What it does, pricing and alternatives. https://meev.ai/reviews/semrush-ai-visibility-toolkit
Cortez, N. (2023). The statutory case against off-label promotion. University of Chicago Law Review Online. https://lawreview.uchicago.edu/sites/default/files/Cortez%20FINAL.pdf
Health Affairs. (2016, June 30). Off-label drug and device promotion. Health Policy Brief. https://www.healthaffairs.org/do/10.1377/hpb20160630.920075/full/
Latham & Watkins LLP. (2025, September 24). FDA begins crackdown on direct-to-consumer pharmaceutical advertising. https://www.lw.com/en/insights/fda-begins-crackdown-on-direct-to-consumer-pharmaceutical-advertising
Artefact. (2026). Health AI assistants: The new front door to healthcare. https://www.artefact.com/?p=1132129
Latham & Watkins LLP. (2025, September 24). FDA begins crackdown on direct-to-consumer pharmaceutical advertising. https://www.lw.com/en/insights/fda-begins-crackdown-on-direct-to-consumer-pharmaceutical-advertising
Made by XDS. (2026, July 17). Fair balance in pharma advertising: FDA rules and examples. https://blog.madebyxds.com/fair-balance-pharma-advertising-rules-examples
U.S. Food and Drug Administration. (2026, August 9). Risk Evaluation and Mitigation Strategies (REMS). https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems
U.S. Food and Drug Administration. (2020, February 1). Compliance program guidance: REMS. https://fda.gov/media/111789/download
Datashake. (2026, March 30). Adverse event monitoring on social media: What pharma teams need to know. https://www.datashake.com/blog/adverse-event-monitoring-on-social-media-what-pharma-teams-need-to-know
Pharmaceutical Commerce. (2026, May 5). FDA’s social media enforcement: Emerging rules of engagement. https://www.pharmaceuticalcommerce.com/view/fdas-social-media-enforcement-emerging-rules-of-engagement
U.S. Food and Drug Administration. (n.d.). Guidance for industry: Postmarketing adverse event reporting for medical products. https://www.fda.gov/media/77193/download
Covington & Burling LLP. (2025, October 17). FDA advertising and promotion enforcement activities: Update. https://www.cov.com/en/news-and-insights/insights/2025/10/fda-advertising-and-promotion-enforcement-activities-update
King & Spalding. (2026, January 21). 2025 year in review: FDA drug and device advertising and promotion enforcement. https://www.kslaw.com/news-and-insights/2025-year-in-review-fda-drug-and-device-advertising-and-promotion-enforcement
Pharmaceutical Technology. (2025, September 17). Big pharma companies hit with FDA warning letters in drug ad clampdown. https://www.pharmaceutical-technology.com/news/big-pharma-companies-hit-with-fda-warning-letters-in-drug-ad-clampdown/; FiercePharma. (2026, January 15). FDA targets Lilly, Novartis, BMS and more in deluge of marketing letters. https://www.fiercepharma.com/marketing/fda-targets-lilly-novartis-bms-and-more-deluge-marketing-letters
Artefact. (2026). Health AI assistants: The new front door to healthcare. https://www.artefact.com/?p=1132129
Pharmacy Times. (2026, May 9). How the FDA is using AI to monitor drug advertising and ensure compliance. https://www.pharmacytimes.com/view/how-the-fda-is-using-ai-to-monitor-drug-advertising-and-ensure-compliance
ClinicalLeader. (2026, January 19). AI at the FDA: Legal implications and strategic considerations for drug developers. https://www.clinicalleader.com/doc/ai-at-the-fda-legal-implications-and-strategic-considerations-for-drug-developers-0001
Hogan Lovells. (2026, May 9). FDA AI tool Elsa 4.0 and HALO unveiled. https://www.hoganlovells.com/en/publications/fda-ai-tool-elsa-40-and-halo-unveiled
Applied Clinical Trials Online. (2026, January 29). FDA and EMA align on ten principles to guide artificial intelligence use in drug development. https://www.appliedclinicaltrialsonline.com/view/fda-ema-align-ten-principles-artificial-intelligence-use-drug-development
Artefact. (2026). Health AI assistants: The new front door to healthcare. https://www.artefact.com/?p=1132129
Zelthy. (2026). AI output compliance monitoring. https://www.zelthy.com/blog/AI-output-compliance-monitoring
Zelthy. (2026). AI output compliance monitoring. https://www.zelthy.com/blog/AI-output-compliance-monitoring
Trakkr. (2026). Best AI visibility tools for pharmaceutical companies. https://trakkr.ai/resources/industry-tools/best-ai-visibility-tools-for-pharmaceutical-companies
NoGood. (2026). The 9 best GEO and AEO tools for pharma and healthcare brands in 2026. https://nogood.io/blog/best-aeo-geo-tools-healthcare-pharma
